Table 2.
Two-year persistence by treatment cohort overall and in selected subgroups among patients without malignancy at baseline initiating treatment in 2010–2016
| 2-year persistence | ||||
|---|---|---|---|---|
| Treatment cohort | N at follow-up start | n | % (95% CI) | |
| Overall | Alendronate | 85,486 | 50,749 | 58.7 (58.4–59.1) |
| Risedronate | 594 | 171 | 28.0 (24.5–31.8) | |
| Ibandronate | 4073 | 1789 | 42.9 (41.3–44.4) | |
| Denosumab | 11,054 | 8007 | 71.9 (71.0–72.7) | |
| Women | Alendronate | 67,697 | 40,720 | 59.6 (59.3–60.0) |
| Risedronate | 523 | 152 | 28.3 (24.6–32.4) | |
| Ibandronate | 3617 | 1585 | 42.8 (41.2–44.4) | |
| Denosumab | 9911 | 7220 | 72.3 (71.5–73.2) | |
| Men | Alendronate | 17,789 | 10,029 | 55.2 (54.5–55.9) |
| Risedronate | 71 | 19 | 25.5 (16.7–37.7) | |
| Ibandronate | 456 | 204 | 43.4 (38.9–48.1) | |
| Denosumab | 1143 | 787 | 68.0 (65.2–70.7) | |
| Restricted to recent osteoporosis treatment users | Alendronate | 3132 | 1989 | 63.0 (61.3–64.7) |
| Risedronate | 427 | 120 | 27.4 (23.4–32.0) | |
| Ibandronate | 2780 | 1201 | 42.2 (40.3–44.0) | |
| Denosumab | 6980 | 5259 | 74.9 (73.9–75.9) | |
| Restricted to past osteoporosis treatment users | Alendronate | 1544 | 768 | 49.1 (46.6–51.6) |
| Risedronate | 60 | 12 | 18.6 (10.6–31.6) | |
| Ibandronate | 508 | 172 | 32.2 (28.3–36.6) | |
| Denosumab | 2563 | 1735 | 66.9 (65.1–68.8) | |
| Restricted to osteoporosis naïve patients | Alendronate | 80,810 | 47,992 | 58.7 (58.4–59.1) |
| Risedronate | 107 | 39 | 35.4 (27.0–45.5) | |
| Ibandronate | 785 | 416 | 52.2 (48.7–55.8) | |
| Denosumab | 1511 | 1013 | 66.4 (64.0–68.8) | |
| Restricted to patients with a history of vertebral fracture before the index date | Alendronate | 2607 | 1525 | 57.8 (55.9–59.7) |
| Risedronate | 12 | 5 | 41.7 (18.8–75.3) | |
| Ibandronate | 118 | 54 | 43.5 (34.9–53.3) | |
| Denosumab | 569 | 416 | 72.2 (68.4–75.9) | |
| Restricted to patients with a history of hip fracture before the index date | Alendronate | 7829 | 4952 | 62.5 (61.4–63.6) |
| Risedronate | 35 | 14 | 40.0 (25.7–58.5) | |
| Ibandronate | 268 | 125 | 45.0 (39.2–51.3) | |
| Denosumab | 1111 | 774 | 68.8 (66.0–71.5) | |
| Restricted to patients with a history of humerus and/or forearm fracture before the index date | Alendronate | 16,131 | 9886 | 60.7 (60.0–61.5) |
| Risedronate | 115 | 40 | 34.3 (26.3–43.9) | |
| Ibandronate | 806 | 363 | 43.8 (40.4–47.4) | |
| Denosumab | 2706 | 1936 | 70.9 (69.2–72.7) | |
| Restricted to patients with no history of any major osteoporotic fracture before the index date | Alendronate | 62,021 | 36,380 | 58.0 (57.6–58.4) |
| Risedronate | 446 | 119 | 25.7 (21.9–30.1) | |
| Ibandronate | 2998 | 1301 | 42.4 (40.6–44.2) | |
| Denosumab | 7316 | 5330 | 72.4 (71.3–73.4) | |
| Restricted to patients with a history of dxa procedure before the index date | Alendronate | 66,079 | 39,244 | 58.8 (58.4–59.2) |
| Risedronate | 513 | 147 | 28.0 (24.3–32.1) | |
| Ibandronate | 3544 | 1552 | 42.8 (41.2–44.5) | |
| Denosumab | 10,200 | 7407 | 72.1 (71.2–73.0) | |